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ABSTRACT 
Foot-and-mouth disease is a highly contagious disease 
that produces severe economic losses in the livestock 
industry. This disease is being controlled by the use of 
an inactivated vaccine. However, the use of recombi- 
nant empty capsids as a subunit vaccine has been re- 
ported to be a promising candidate because it avoids 
the use of virus in the vaccine production. A plasmid 
containing the capsid precursor P12A and protease 
3C sequences of foot-and-mouth disease virus (FMDV) 
was constructed and used to compare transient and 
stable expression in mammalian cells. When BHK-21 
cells were transfected with the recombinant vector, 
protease 3C cleaved the capsid precursor P12A into 
the structural proteins VP0, VP1 and VP3. A sucrose 
gradient demonstrated that the structural proteins 
assembled into different subviral particles. Attempts 
to generate a stable cell line only allowed isolating 
low-level-expressing clones, probably due to the effect 
of protease 3C on the cells. Moreover, the recombi- 
nant protein yield achieved in transient expression as- 
says was much higher than the one achieved in stable 
expression assays. Results indicate that mammalian 
cells are a good strategy to produce recombinant 
FMDV subviral particles. However, the alternative 
approach of transient gene expression in scalable sys- 
tems should be used instead of the standard method 
that involves the generation of a stable cell line. 
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1. INTRODUCTION 
Foot-and-mouth disease virus (FMDV) is a highly con- 
tagious virus of cloven-hoofed animals, which belongs to  
the Picornaviridae family [1]. Its genome encodes a 
polyprotein that is processed by virus-encoded proteases 
into structural and non-structural proteins. The viral 
capsid precursor P12A is cleaved by protease 3C into the 
capsid proteins VP0, VP3 and VP1, which spontaneously 
self-assemble into different subviral particles. One copy 
of VP0, VP3 and VP1 forms the protomer (5S), five pro- 
tomers assemble into the pentamer (12S) and twelve 
pentamers form the empty capsid (75S) [2]. Cleavage of 
VP0 into VP2 and VP4 occurs upon encapsidation of 
genomic RNA.  
Nowadays, vaccination is the main means of foot-and- 
mouth disease (FMD) control in most endemic areas. 
The vaccine is produced by growing FMDV in BHK-21 
cell cultures under biosecured conditions [3]. Although 
this vaccine has proved to be effective in preventing the 
disease, its production entails a number of disadvantages, 
including the risk of virus escape, the problem of dis- 
criminating between vaccinated and infected animals, 
and difficulties of certain serotypes and subtypes to grow 
well in cell cultures [4]. To overcome these problems, 
new approaches intend to find alternatives that could 
provide the immunogenicity of the current vaccine while 
avoiding the handling of large quantities of infectious 
virus [5]. Among these, empty capsids appear to provide 
an excellent subunit vaccine candidate because FMDV 
empty capsids are naturally produced in infected cells 
and are as immunogenic as virions. Many approaches for 
the production of FMDV empty capsids have mainly 
focused on the use of the baculovirus expression system 
and recently the use of recombinant vaccinia virus [6-8]. 
However, the use of nonviral vectors in mammalian cells 
has been poorly explored. Mammalian cell expression 
system can be used for transient or stable expression 
depending upon the purpose and the properties of the 
recombinant protein. For stable expression the gene of 
interest must integrate into the genome of the host cell.  
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Although the process is tedious and time consuming, 
once the cell line is established it represents an unlimited 
source of protein. For transient expression, after trans- 
fection with a recombinant plasmid, production of the 
recombinant protein will occur until the cells are har- 
vested. The gene of interest is not integrated into the 
genome of the host cells. Transient expression is an alter- 
native and feasible approach for the production of toxic 
proteins that impairs the isolation if stable clones [9]. 
The production of recombinant FMDV empty capsids re- 
quires the expression of the poliprotein P12A and pro- 
tease 3C. Protease 3C has been reported to cleave not 
only the FMDV capsid precursor but also histones and 
initiation transcription factors of the host cell [10,11]. 
Thus, since protease 3C can affect protein expression it 
can affect the isolation of high expressing clones. In 
order to determine the best strategy for the production of 
FMDV empty capsids, we compared transient and stable 
expression in BHK-21 cells using a recombinant plas- 
mid. 
2. MATERIALS AND METHODS 
2.1. Cells and Viruses 
Baby hamster kidney cell (BHK-21) monolayers were 
grown in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% fetal bovine serum (FBS) in a 
humidified incubator at 37˚C with 5% CO2. FMDV 
serotype A/Arg/01 inactivated with binary ethyleneimine 
and purified by sucrose gradient was used as a positive 
control for protein characterization assays. 
2.2. Plasmids 
Gene fragments encoding for the capsid precursor P12A 
(2258 bp) and protease 3C (687 bp) were amplified by 
PCR from F3A and F3B plasmids (kindly provided by Dr. 
Soledad García Nuñez, Instituto de Biotecnología, INTA, 
Argentina), respectively. F3A and F3B plasmids encoded 
the complete sequence of FMDV A/Arg/01. Amplicons 
were cloned into pGEMT-Easy vector (Promega) and 
subcloned together into the pCI-neo mammalian expres- 
sion vector (Promega). The protease 3C was also cloned 
alone. Plasmids were named pCI-P12A3C and pCI-3C, 
respectively. The primers used for amplification of P12A 
and 3C for the generation of pCI-P12A3C were: P12A 
foward, 5’-GCT AGC GCC GCC ACC ATG GGG GCT 
GGA CAA TCC-3’, P12A reverse, 5’-TTC GAA CCC 
AGG GTT GGA-3’ and 3C foward, 5’-TTC GAA AGT 
GGT GCC CCA CCG-3’, 3C reverse, 5’-CTC GAG TTA 
CAT CAC GTG AAC GCG-3’. The primers used for 
amplification of 3C for the generation of pCI-3C were: 
3C foward, 5’-CTC GAG AAC ATG AGT GGT GCC 
CCA CCG-3’, 3C reverse, 5’-GCT AGC TTA CAT CAC 
GTG GAC GCG-3’. Restriction enzyme sites are indi- 
cated underlined. 
2.3. Protein Expression in BHK-21 Cells 
For transient expression, BHK-21 cells were transfected 
with pCI-P12A3C plasmid in 25 cm2 T-flasks with Lipo- 
fectamine 2000 (Invitrogen) according to the manufac- 
turer’s instructions. Twenty-four hours post-transfection, 
cells were treated with 1.5 ml of lysis buffer (20 mM 
TrisHCl, 137 mM NaCl, 10% (v/v) glycerol, 1% (v/v) 
nonidet P-40, 2 mM EDTA) and analyzed for recom- 
binant protein expression. For stable cell line generation, 
BHK-21 cells were transfected with BamHI-linearized 
pCI-P12A3C and selected in the presence of 700 µg/ml 
geneticin (G-418 sulfate, Gibco-BRL). After 2 weeks of 
selection, surviving cells were subjected to terminal dilu- 
tion and emerging clones were tested for recombinant 
protein expression. 
2.4. Evaluation of the Effect of Protease 3C on 
Protein Expression 
BHK-21 cells were co-transfected with pcDNA-EGFP 
(kindly provided by Dr. Gabriela Calamante, Instituto de 
Biotecnología, INTA, Argentina) and either empty pCI- 
neo vector or pCI-3C in 24 well culture plates with 
Lipofectamine 2000. After 48 hours, cells were observed 
by fluorescent microscopy and analyzed by flow cyto- 
metry using a FACSCalibur (BD biosciences). In order to 
corroborate that the effect observed was due to the act- 
ivity of protease 3C and not to the presence of the rec- 
ombinant plasmid, pCI-3C was linearized with SalI 
(which cleaves inside the 3C gene) or with BstBI (that 
cleaves the vector backbone downstream the stop codon/ 
A tailing). Both vectors were named pCI-3Ci (inactive) 
and pCI-3Ca (active), respectively and were co-trans- 
fected with pcDNA-EGFP. 
2.5. Characterization of FMDV Expressed  
Proteins 
Cell lysates were separated by SDS-PAGE. Separated 
proteins were transferred onto a nitrocellulose mem- 
brane, blocked and then incubated with anti-FMDV gui- 
nea pig serum. After several washes, membranes were 
incubated with horseradish peroxidase-conjugated anti- 
guinea pig goat serum (KPL). The reaction was visua- 
lized with an enhanced chemiluminescence method. 
Quantification of recombinant proteins was carried out 
by enzyme-linked immunosorbent assay (ELISA). Bri- 
efly, microtiter plates (Immunolon II) were coated with 
anti-FMDV rabbit serum (1/3000) in carbonate-bicar- 
bonate buffer, pH 9.6, at 4˚C overnight. After washing 
and blocking, cell lysates were added and incubated on 
plates at 37˚C for an hour. Known amounts of purified 
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inactivated FMDV were two-fold serially diluted and 
added to the wells for standard curve generation. Plates 
were then incubated with anti-FMDV guinea pig serum, 
followed by horseradish peroxidase-conjugated anti- 
guinea pig goat serum (KPL). O-phenylenediamine- 
H2O2 was used as substrate. The reaction was stopped 
with sulphuric acid 12%. Optical density was recorded at 
492 nm (OD492) in a microplate reader (Thermo Sci- 
entifics Multiskan FC). Structural protein characteriza- 
tion was carried out by ELISA using four different mo- 
noclonal antibodies (MAbs 1-5, 2-4, 3-3 and 3-2) 
directed to conformational epitopes of FMDV A/Arg/ 01 
[12]. Lysates of transfected cells were loaded onto a 45% 
- 15% sucrose gradient and centrifuged at 50,000 g 16 h 
in a SW28 rotor at 4˚C. Fractions were collected and 
tested by ELISA. Inactivated FMDV A/Arg/2001 was 
run at the same conditions and used as positive control. 
3. RESULTS AND DISCUSSION 
The polyprotein P12A and protease 3C genes from 
FMDV serotype A/Arg/01 were amplified and cloned 
into the pCI-neo vector. Immunoprecipitation and West- 
ern blotting were used to determine the correct expres- 
sion of the poliprotein P12A and protease 3C after 
transient transfection. As shown in Figure 1 the P12A 
precursor was successfully cleaved by protease 3C into 
the structural proteins VP0 (37 kDa), VP3 (23 kDa) and 
VP1 (23 kDa). 
In order to determine if the structural proteins as- 
sembled into subviral particles, the lysates of cells trans- 
fected with pCI-P12A3C were analyzed by ELISA using 
MAbs directed to conformational epitopes of FMDV 
A/Arg/2001 [12]. The recombinant proteins and the virus 
were recognized by the four assayed MAbs (Figure 2(a)) 
suggesting that the structural proteins VP0, VP3 and VP1 
assembled together into subviral particles. 
 
 
Figure 1. Western blot analysis of recombinant proteins im- 
munoprecipitated with an anti-FMDV mouse serum. Protein 
extracts were run on SDS-page, transferred onto a nitrocel- 
lulose membrane, and a guinea pig serum against FMDV was 
used as primary antibody. 
 
Figure 2. (a) Antigenic reactivity of purified FMDV 
and lysates of pCI-P12A3C or mock-transfected cells 
with MAbs: 1-5, 2-4, 3-2 and 3-3; (b) Inactivated 
FMDV and lysates of pCI-P12A3C or mock-trans- 
fected cells were loaded onto a 45% - 15% sucrose 
gradient. Fractions were collected and analyzed by 
solid phase ELISA. Known positions of the FMDV 
virions (146S), empty capsids (75S), pentamers (12S) 
and protomers (5S) are indicated. 
 
Sedimentation in a 45% - 15% sucrose gradient was 
used to further analyze the ability of structural proteins to 
assemble into particulate subunits. Even though we were 
able to detect protomers (5S) and pentamers (12S) (Fig- 
ure 2(b)), it was not possible to detect empty capsids in 
the lysates of transfected cells.  
For the production of stable clones, BHK-21 cells 
were transfected with pCI-P12A3C and after selection 
and terminal dilution; the emerging clones were analyzed 
by ELISA for protein expression.  
Three out of 36 clones were positive for recombinant 
protein expression (Figure 3(a)). The polyproteinP12A 
and protease 3C genes were confirmed to be correctly 
integrated into genomic DNA of these clones by PCR 
amplification (Figure 3(b)). 
A simple co-transfection assay was used to evaluate 
the effect of protease 3C on protein expression in 
BHK-21 cells. EGFP expression decreased dramatically 
in cells co-transfected with pCI-3C but not in cells 
co-transfected with pCI-neo (empty vector) (Figure 
4(a)). Also, co-transfection with pCI-3Ca resulted in a    
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Figure 3. Analysis of stably transfected clones. (a) Lysates of G418 resistant clones were analyzed by ELISA 
for the expression of recombinant proteins. The cut-off value was calculated as mean O.D. 492 nm + 3 SD 
(black line); (b) Genomic DNA was purified and fragments of P12A (2258 bp) and protease 3C (687 bp) were 
PCR-amplified from positive clones N˚18, 20 and 36 (lanes 2-4). DNA from parental cells was used as 
negative control (lane 1) and pCI-P12A3C plasmid as positive control (lane 5). MW: DNA molecular weight 
marker. 
 
decreased EGPF expression compared to expression lev- 
els when co-transfecting with pCI-3Ci (Figure 4(b)). 
 
Thus, the activity of the protease 3C is probably 
impairing the isolation of high-level expressing clones. It 
is worth pointing out that many recombinant viral vec- 
tors encoding the P12A3C expression cassette were suc- 
cessfully generated [8,13,14] while others could not be 
isolated [15,16]. 
This difference could be attributed to a different 
susceptibility of the host cells to protease 3C. Thus, other 
cell lines, such as Vero and HEK 293 (in which the de- 
velopment of recombinant viral vector was successful), 
were tested with the EGFP-co-transfection assay, but the 
same results were observed (data not shown). This 
suggests that the development of stable clones in other 
cell lines does not seem to be an appropriate approach to 
increase expression levels. The strategy of cloning the 
cDNA sequences of individual structural proteins (VP0, 
VP1 and VP3) to generate stable cell lines is complicated 
and tedious because a sequential selection process is 
needed. Moreover, it has been previously reported that 
the assembly of subviral particles of picornavirus from 
individual structural proteins is less efficient than that 
obtained from the P12A3C expression cassette [17]. 
Figure 4. Analysis of the effect of protease 3C on 
protein expression. Mean fluorescence intensity of 
cells co-transfected with pCDNA-EGFP and (a) 
pCI-empty or pCI-3C; (b) pCI-3Ci or pCI-3Ca. 
Error bars represent standard deviations derived 
from duplicate independent experiments. 
 
 Recombinant protein yield was about 0.014 ug/ml in 
stable clones and 0.15 ug/ml in transiently transfected 
cells (Figure 5). Therefore, for the production of rec- 
ombinant FMDV capsid proteins in mammalian cells, the 
strategy of transient gene expression should be used 
instead of the generation of a stable cell line. However, 
further studies should be done in order to increase the 
expression levels and make transient transfection a suit- 
able strategy for FMD vaccine production. 
Figure 5. Comparison of expression levels in stable 
clones and transiently transfected cells. Lysates were 
analyzed by ELISA for the expression of recombinant 
proteins. Error bars represent standard deviations de- 
rived from triplicates independent experiments. 
 
higher-order structures is strongly influenced by the 
concentration of individual proteins [18], with this sys- 
tem we are probably below the critical threshold concen- 
tration of pentamers that is required before capsid for- 
mation can occur. 
Results obtained in this study show that mammalian 
cells are a suitable expression system for the production 
of subviral particles of FMDV A/Arg/01. FMDV proto- 
mers and pentamers were produced when BHK-21 cells 
were transiently transfected. Since the formation of  
When we compared stable and transient expression we 
determined that expression levels in lysates of transiently 
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transfected cells were higher than those achieved in 
lysates of stable clones. 
This might be due to the effect of protease 3C on the 
cells. However, these expression levels are still below 
the ones needed for vaccine development. Thus, further 
studies should be done to optimize expression levels 
achieved by transient gene expression. The use of sus- 
pension-growing cells, serum free medium and economic 
transfection reagents is some of the improvements that 
could be explored [19]. Several authors have reported 
high expression levels that are compatible with the de- 
velopment of a vaccine (0.55 - 80 mg/ml of cell culture) 
using transient gene expression [9]. Moreover, in the 
particular case of toxic proteins, transient expression 
seems to be the only possible approach [20]. For all the 
reasons mentioned above, further studies should be done 
in order to make transient transfection a suitable strategy 
for FMD vaccine production. 
4. ACKNOWLEDGEMENTS 
We thank Dr. Osvaldo Zabal and his group for providing valuable help 
on cell culture, Diego Compaired for technical assistance and Dr. María 
José Gravisaco and Lic. Mariela Gammella for helping with flow 
cytometry assays. This work was supported by grants PAE-PICT- 
2001-00044 from Agencia Nacional de Promoción Científica y Tecno- 
lógica, Argentina and PE AESA201721 from Instituto Nacional de 
Tecnología Agropecuaria, Argentina. 
 
REFERENCES 
[1] Grubman, M. and Baxt, B. (2004) Foot-and-mouth dis- 
ease. Clinical Microbiology Reviews, 17, 465-493. 
http://dx.doi.org/10.1128/CMR.17.2.465-493.2004 
[2] Belsham, G. (1993) Distinctive features of foot-and- 
mouth disease virus, a member of the picornavirus family; 
aspects of virus protein synthesis, protein processing and 
structure. Progress in Biophysics and Molecular Biology, 
60, 241-260.  
http://dx.doi.org/10.1016/0079-6107(93)90016-D 
[3] Doel, T.R. (2003) FMD vaccines. Virus Research, 91, 
81-99. http://dx.doi.org/10.1016/S0168-1702(02)00261-7 
[4] Parida, S. (2009) Vaccination against foot-and-mouth dis- 
ease virus: Strategies and effectiveness. Expert Reviews 
Vaccines, 8, 347-365. 
http://dx.doi.org/10.1586/14760584.8.3.347 
[5] Grubman, M.J. (2005) Development of novel strategies to 
control foot-and-mouth disease: Marker vaccines and 
antivirals. Biologicals, 33, 227-234. 
http://dx.doi.org/10.1016/j.biologicals.2005.08.009 
[6] Cao, Y., Lu, Z., Sun, J., Bai, X., Sun, P., Bao, H., et al. 
(2009) Synthesis of empty capsid-like particles of Asia I 
foot-and-mouth disease virus in insect cells and their 
immunogenicity in guinea pigs. Veterinary Microbiology, 
137, 10-17.  
http://dx.doi.org/10.1016/j.vetmic.2008.12.007 
[7] Li, Z., Yi, Y., Yin, X., Zhang, Y., Liu, M., Liu, H., et al. 
(2012) Development of a foot-and-mouth disease virus 
serotype A empty capsid subunit vaccine using silkworm 
(Bombyx mori) pupae. PLoS One, 7, e43849. 
http://dx.doi.org/10.1371/journal.pone.0043849 
[8] Porta, C., Kotecha, A., Burman, A., Jackson, T., Ren, J., 
Loureiro, S., et al. (2013) Rational engineering of recom- 
binant picornavirus capsids to produce safe, protective 
vaccine antigen. Plos Pathogens, 9, e1003255.  
http://dx.doi.org/10.1371/journal.ppat.1003255 
[9] Baldi, L., Hacker, D.L., Adam, M. and Wurm, F.M. 
(2007) Recombinant protein production by large-scale 
transient gene expression in mammalian cells: State of 
the art and future perspectives. Biotechnolology Letters, 
29, 677-684.  
http://dx.doi.org/10.1007/s10529-006-9297-y 
[10] Capozzo, A.V.E., Burke, D.J., Fox, J.W., Bergmann, I.E., 
La Torre, J.L. and Grigera, P.R. (2002) Expression of 
foot and mouth disease virus non-structural polypeptide 
3ABC induces histone H3 cleavage in BHK-21 cells. Vi- 
rus Research, 90, 91-99. 
http://dx.doi.org/10.1016/S0168-1702(02)00140-5 
[11] Strong, R. and Belsham, G.J. (2004) Sequential modifica- 
tion of translation initiation factor eIF4GI by two differ- 
ent foot-and-mouth disease virus proteases within in- 
fected baby hamster kidney cells: Identification of the 
3Cpro cleavage site. Journal of General Virology, 85, 
2953-2962. http://dx.doi.org/10.1099/vir.0.80254-0 
[12] Seki, C., Robiolo, B., Periolo, O., Iglesias, M., D’An- 
tuono, A., Maradei, E., et al. (2009) Rapid methodology 
for antigenic profiling of FMDV field strains and for the 
control of identity, purity and viral integrity in comer- 
cial virus vaccines using monoclonal antibodies. Veteri- 
nary Microbiology, 133, 239-251. 
http://dx.doi.org/10.1016/j.vetmic.2008.07.011 
[13] D’Antuono, A., Laimbacher, A.S., La Torre, J., Tribulatti, 
V., Romanutti, C., Zamorano, P., et al. (2010) HSV-1 
amplicon vectors that direct the in situ production of foot- 
and-mouth disease virus antigens in mammalian cells can 
be used for genetic immunization. Vaccine, 28, 7363- 
7372. http://dx.doi.org/10.1016/j.vaccine.2010.09.011 
[14] Zhou, G., Wang, H., Wang, F. and Yu, L. (2012) Recom- 
binant adenovirus expressing type Asia1 foot-and-mouth 
disease virus capsid proteins induces protective immunity 
against homologous virus challenge in mice. Research in 
Veterinary Science, 5, 1-7. 
http://dx.doi.org/10.1016/j.rvsc.2012.12.004 
[15] Abrams, C.C., King, M.Q. and Belsham, G.J. (1995) 
Assembly of foot-and-mouth disease virus empty capsids 
synthesized by a vaccinia virus expression system. Jour- 
nal of General Virology, 76, 3089-3098. 
http://dx.doi.org/10.1099/0022-1317-76-12-3089 
[16] Klopfleisch, C., Minh, L.Q., Giesow, K., Curry, S. and 
Keil, G.M. (2010) Effect of foot-and-mouth disease virus 
capsid precursor protein and 3C protease expression on 
bovine herpesvirus 1 replication. Archives of Virology, 
155, 723-731.  
http://dx.doi.org/10.1007/s00705-010-0648-6 
[17] Brautigam, S., Snezhkov, E. and Bishop, D.H.L. (1993) 
Copyright © 2013 SciRes.                                                                       OPEN ACCESS 
A. C. Mignaqui et al. / Advances in Bioscience and Biotechnology 4 (2013) 1024-1029 
Copyright © 2013 SciRes.                                                                       
1029
OPEN ACCESS 
Formatios of poliovirus-like particles by recombinant 
baculoviruses expressing the individual VP0, VP3 and 
VP1 proteins by comparison to particles derived from the 
expressed poliovirus polyprotein. Virology, 192, 512-524. 
http://dx.doi.org/10.1006/viro.1993.1067 
[18] Goodwin, S., Tuthill, T.J., Arias, A., Killington, R.A. and 
Rowlands, D.J. (2009) Foot-and-mouth disease virus as-
sembly: Processing of recombinant capsid precursor by 
exogenous protease induces self-assembly of pentamers 
in vitro in a myristoylation-dependent manner. Journal of 
Virolology, 83, 11275-11282. 
http://dx.doi.org/10.1128/JVI.01263-09 
[19] Pham, P.L., Kamen, A. and Durocher, Y. (2006) Large- 
scale transfection of mammalian cells for the fast produc- 
tion of recombinant protein. Molecular Biotechnology, 34, 
225-237. http://dx.doi.org/10.1385/MB:34:2:225 
[20] Nallet, S., Amacker, M.,Westerfeld, N., Baldi, L., König, 
I., Hacker, D.L., et al. (2009) Respiratory syncytial virus 
subunit vaccine based on a recombinant fusion protein 
expressed transiently in mammalian cells. Vaccine, 27, 
6415-6419. 
http://dx.doi.org/10.1016/j.vaccine.2009.06.019 
 
 
 
 
 
